Safety and immunogenicity of candidate tuberculosis (TB) vaccine MVA85A administered by the intramuscular route and the intradermal route: a phase I randomised active controlled trial.

Trial Profile

Safety and immunogenicity of candidate tuberculosis (TB) vaccine MVA85A administered by the intramuscular route and the intradermal route: a phase I randomised active controlled trial.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Sep 2016

At a glance

  • Drugs MVA 85A (Primary)
  • Indications Tuberculosis
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Mar 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Aug 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
    • 28 Dec 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top